Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN

Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN
Guatemala, 01010
Select an option

Open studies

Hiv
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) - Merck Sharp & Dohme LLCSee more
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) - Merck Sharp & Dohme LLCSee more
Non-Hodgkin Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) - waveLINE-010 - Merck Sharp & Dohme LLCSee more
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) - waveLINE-003 - Merck Sharp & Dohme LLCSee more
Prostate cancer
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) - OMAHA-004 - Merck Sharp & Dohme LLCSee more
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) - OMAHA-004 - Merck Sharp & Dohme LLCSee more
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloadsCareers
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy